Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research14

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research14

FiltersClear all

Status

Recruiting3
Active, not recruiting5
Completed3
Terminated3

Study type

Interventional14

Phase

Phase 26
Not applicable4
Phase 33
Phase 1/21

Investigator

Jean W. Pape3
Ashish Saxena1
Adam Buckholz1
Camilia Rivera Martin1
Eleni Andreopoulou1

Department

Medicine11
Neurology1
Pediatrics1
Surgery1

Condition

Tuberculosis2
Brain Diseases, Metabolic1
Breast Neoplasms1
Burkitt Lymphoma1
Carcinoma, Non-Small-Cell Lung1

Intervention type

Dietary supplement14
Drug788
Other176
Device166
Biological150
Procedure

Sponsor type

Other academic4
WCM (investigator-initiated)4
NIH3
Cooperative group2
Industry1

Start date

Has results posted5

Interventional×Dietary supplement×Clear all

Showing 1–14 of 14 studiesSort:

Active, not recruitingInterventional · Phase 3NCT03568383 ↗
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)

FiltersClear all

Status

Recruiting3
Active, not recruiting5
Completed3
Terminated3

Study type

Interventional14

Phase

Phase 26
Not applicable4
Phase 33
Phase 1/21

Investigator

Jean W. Pape3
Ashish Saxena1
Adam Buckholz1
Camilia Rivera Martin1
Eleni Andreopoulou1

Department

Medicine11
Neurology1
Pediatrics1
Surgery1

Condition

Tuberculosis2
Brain Diseases, Metabolic1
Breast Neoplasms1
Burkitt Lymphoma1
Carcinoma, Non-Small-Cell Lung1

Intervention type

Dietary supplement14
Drug788
Other176
Device166
Biological150
Procedure

Sponsor type

Other academic4
WCM (investigator-initiated)4
NIH3
Cooperative group2
Industry1

Start date

Has results posted5

Interventional×Dietary supplement×Clear all

Showing 1–14 of 14 studiesSort:

Active, not recruitingInterventional · Phase 3NCT03568383 ↗
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)

Show all 12

Show fewer

Michal Bar-Natan Zommer1
Jyoti S. Mathad1
Lisa Mosconi1
Massimo Cristofanilli1
Manish A Shah1
Mehraneh Dorna Jafari1
Randy Longman1

Show all 21

Show fewer

Colitis, Ulcerative1
Colorectal Neoplasms1
Diabetes Mellitus, Type 21
Diabetes, Gestational1
Fibrosis1
HIV Infections1
Hepatic Encephalopathy1
Hypertension, Portal1
Inflammatory Bowel Diseases1
Leukemia, Biphenotypic, Acute1
Parasomnias1
Precursor Cell Lymphoblastic Leukemia-Lymphoma1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma1
Premature Birth1
Sleep Initiation and Maintenance Disorders1
Tuberculosis, Multidrug-Resistant1

119

Behavioral83

Radiation61

Diagnostic test22

Combination product11

Genetic6

Jean W. PapePI

Intervention: Drug: Delamanid (DLM) · Drug: Isoniazid (INH) · Dietary supplement: Pyridoxine (vitamin B6)
Dates: Jun 2019 – Nov 2026 (est.)
Sponsor: National Institute of Allergy & Infectious Diseases

Tuberculosis, MDR

Active, not recruitingInterventional · Phase 3NCT04094688 ↗

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Manish A ShahPI

Intervention: Drug: Bevacizumab · Drug: Oxaliplatin · Drug: Leucovorin Calcium · Drug: Fluorouracil · Drug: Irinotecan Hydrochloride · Drug: Irinotecan · Dietary supplement: Cholecalciferol · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Dates: Oct 2019 – Jul 2024· Results posted
Sponsor: Alliance for Clinical Trials in Oncology

Colorectal Adenocarcinoma

Active, not recruitingInterventional · Phase 2NCT05090358 ↗

Targeting Insulin Feedback to Enhance Alpelisib (TIFA): A Phase 2 Randomized Control Trial in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast Cancer

Eleni AndreopoulouPI

Intervention: Dietary supplement: Ketogenic Diet · Dietary supplement: Low Carbohydrate Diet · Drug: Alpelisib · Drug: Fulvestrant · Drug: Canagliflozin
Dates: Oct 2021 – Oct 2027 (est.)
Sponsor: Memorial Sloan Kettering Cancer Center

Breast CancerBreast Cancer Stage IVMetastatic Breast Cancer

RecruitingInterventional · Not applicableNCT05380401 ↗

Metabolic Mechanisms Induced by Enteral Docosahexaenoic Acid (DHA) and Arachidonic Acid (ARA) Supplementation in Preterm Infants

Camilia Rivera MartinPI

Intervention: Dietary supplement: Enfamil® DHA & ARA Supplement for Special Dietary Use
Dates: Mar 2023 – Apr 2027 (est.)
Sponsor: University of Texas Health Science Center at San Antonio

Premature

Active, not recruitingInterventional · Phase 3NCT05602194 ↗

A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy

Michal Bar-Natan ZommerPI

Intervention: Procedure: Biospecimen Collection · Drug: Calaspargase Pegol · Dietary supplement: Levocarnitine · Drug: Pegaspargase · Other: Quality-of-Life Assessment
Dates: Aug 2023 – Sep 2026 (est.)
Sponsor: Children's Oncology Group

B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(922)(q34.1+6 more

Active, not recruitingInterventional · Phase 2NCT05664477 ↗

PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial

Lisa MosconiPI

Intervention: Dietary supplement: PhytoSERM · Drug: Placebo
Dates: Jan 2024 – Jan 2027 (est.)
Sponsor: University of Arizona

MenopauseCognitive ChangeBrain Disorder, Metabolic

RecruitingInterventional · Not applicableNCT06209411 ↗

A Type 2 Hybrid Effectiveness-Implementation Trial of Community Health Workers to Improve Screening for Postpartum Diabetes in Urban Slums of India

Jyoti S. MathadPI

Intervention: Behavioral: Home Based Testing · Behavioral: Clinic Based Screening · Dietary supplement: Food order nutritional intervention before meals · Dietary supplement: Food order nutritional intervention after meals
Dates: Jun 2024 – Feb 2027 (est.)
Sponsor: Weill Medical College of Cornell University

Diabetes Mellitus, Type 2Gestational Diabetes

RecruitingInterventional · Not applicableNCT07046429 ↗

Effect of Supplemental Nightly Melatonin On REM and Cognition in Hepatic Encephalopathy (SNORE-HE) Trial

Adam BuckholzPI

Intervention: Dietary supplement: Melatonin tablet 3 mg once daily · Dietary supplement: Thiamine
Dates: Aug 2025 – Dec 2026 (est.)
Sponsor: Weill Medical College of Cornell University

Hepatic EncephalopathyCovert Hepatic EncephalopathyCirrhosis+1 more

CompletedInterventional · Phase 2NCT01936831 ↗

The Early Bactericidal Activity of High-Dose or Standard-Dose Isoniazid Among Adult Participants With Isoniazid-Resistant or Drug-Sensitive Tuberculosis

Jean W. PapePI

Intervention: Drug: Isoniazid · Dietary supplement: Vitamin B6
Dates: Aug 2014 – Sep 2021· Results posted
Sponsor: National Institute of Allergy & Infectious Diseases

Tuberculosis

CompletedInterventional · Phase 2NCT03998488 ↗

A Randomized, Placebo-controlled Clinical Trial Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Subsequent Dietary Fiber in Patients With Moderate Ulcerative Colitis

Randy LongmanPI

Intervention: Drug: Fecal Microbiota Transplantation · Dietary supplement: Psyllium Husk Powder
Dates: Jan 2020 – Jun 2023· Results posted
Sponsor: Weill Medical College of Cornell University

Ulcerative ColitisInflammatory Bowel Diseases

TerminatedInterventional · Phase 2NCT04265534 ↗

A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Ashish SaxenaPI

Intervention: Drug: Telaglenastat · Drug: Carboplatin Chemotherapy · Drug: Pemetrexed Chemotherapy · Biological: Pembrolizumab Immunotherapy · Drug: Placebo · Dietary supplement: Folic acid 400 -1000 μg · Dietary supplement: Vitamin B12 1000 μg · Drug: Dexamethasone 4 mg
Dates: Jul 2020 – Nov 2021
Sponsor: Calithera Biosciences, Inc.

Non-Small Cell Lung CancerNon-squamous Non-small-cell Lung CancerNon-Squamous Non-Small Cell Neoplasm of Lung+3 more

TerminatedInterventional · Phase 2NCT04272242 ↗

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

Jean W. PapePI

Intervention: Drug: Dolutegravir (DTG) · Drug: Isoniazid (INH) · Drug: Rifapentine (RPT) · Drug: Antiretroviral Therapy (ART) · Dietary supplement: Pyridoxine (Vitamin B6)
Dates: Feb 2021 – Dec 2021· Results posted
Sponsor: National Institute of Allergy & Infectious Diseases

HIV InfectionLTBI

CompletedInterventional · Not applicableNCT05136092 ↗

A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors

Mehraneh Dorna JafariPI

Intervention: Dietary supplement: Cohort 1: HFCS (fructose) fed · Dietary supplement: Cohort 2: D-Xylose (xylose-fed)
Dates: Feb 2022 – Aug 2024
Sponsor: Weill Medical College of Cornell University

Colorectal Tumors

TerminatedInterventional · Phase 1/2NCT05198843 ↗

Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients With Metastatic Triple-Negative Inflammatory Breast Cancer

Massimo CristofanilliPI

Intervention: Drug: Dasatinib · Dietary supplement: Icosapent Ethyl
Dates: Nov 2022 – Dec 2023· Results posted
Sponsor: National Cancer Institute

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Inflammatory Carcinoma